

July 7, 2026
Symbio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

**FY2026 Grant Awarded for Research and Development of Orphan Drug for IV BCV
for Adenovirus Infection Following Hematopoietic Stem Cell Transplantation**

TOKYO, Japan, July 7, 2026 -- Symbio Pharmaceuticals Limited (“Symbio” or the “Company”) today announced that the National Institutes of Biomedical Innovation, Health, and Nutrition (NIBIOHN) has awarded Symbio a grant under 1st round of the FY2026 Grant Program for Research and Development of Orphan Drugs, Orphan Medical Devices and Orphan Regenerative Medicine Products for intravenous brincidofovir (IV BCV), an injectable formulation of brincidofovir being developed by Symbio for the treatment of adenovirus (AdV) infection following hematopoietic stem cell transplantation (HSCT). IV BCV was designated as an orphan drug by Japan’s Minister of Health, Labour and Welfare in September 2025.

AdV infection following HSCT can be fatal and occurs across all age groups, from pediatric to adult patients. As there are no established prevention or treatment options, this remains a therapeutic area with significant unmet medical need. Symbio has initiated a global Phase 3 clinical trial targeting AdV infection following HSCT and patient enrollment is proceeding as planned in Europe and the United States. The Company plans to expand the trial to additional countries going forward.

Statement from Fuminori Yoshida, President and CEO: “Symbio will continue to advance the development of IV BCV for this disease in order to address the serious unmet medical need and contribute to patient care as soon as possible.”

The Company does not expect that this matter will have a material impact on its consolidated financial results for the fiscal year ending December 2026.

Program name: FY2026 Grant Program for Research and Development of Orphan Drugs, Orphan Medical Devices and Orphan Regenerative Medicine Products

Grant period: April 1, 2026, to March 31, 2027. Subsidy applications are to be submitted each fiscal year.

Product name: brincidofovir (injectable brincidofovir, or IV BCV)

Planned indication: Treatment of adenovirus infection in organ transplant recipients (including hematopoietic stem cell transplantation)

[Contact]

Investor Relations

Tel: +81 (0)3 5427 1125

Notes

Orphan Drug Designation

Japan's "Orphan Drug Designation System" administered by the Ministry of Health, Labour and Welfare (MHLW) is intended to support the development of pharmaceuticals and related products for which medical need is high but development has not progressed sufficiently due to the small number of patients. IV BCV was designated by the Minister of Health, Labour and Welfare following consultation with the Pharmaceutical Affairs Council, as it meets the requirements set forth under Article 77-2 of the Pharmaceuticals and Medical Devices Act, including (i) an eligible patient population of fewer than 50,000 in Japan, and (ii) a target disease that is serious or an infectious disease for which the medical need is particularly high. Further details of the system are available on the following MHLW website:

https://www.mhlw.go.jp/english/policy/health-medical/pharmaceuticals/orphan_drug.html

Grant Program for Orphan Diseases

For pharmaceuticals, medical devices and regenerative medicine products targeting intractable diseases, development often lags because, despite high medical need, the number of patients is small and it is difficult to recoup R&D investments. To promote development, Japan has a system to designate qualifying products as orphan drugs, orphan medical devices, or orphan regenerative medicine products. As one of the support measures, companies may receive grants through NIBIOHN to reduce the financial burden of development-related expenses.

BCV Business Strategy Based on Three Therapeutic Pillars

Since acquiring the global license to BCV in September 2019, SymBio has pursued collaborative research with world-class research institutions to unlock BCV's potential in three therapeutic areas. SymBio is currently concentrating management resources

on development centered on three pillars: (1) viral infections following HSCT, (2) hematologic malignancies and solid tumors, and (3) neurodegenerative diseases, and aims to maximize the business value of BCV through global business expansion.